By Professor David Goldstein

Journal articles

Greiner JW; Guadagni F; Goldstein D; Smalley RV; Borden EC; Simpson JF; Molinolo A; Schlom J, 1992, 'Intraperitoneal administration of interferon-gamma to carcinoma patients enhances expression of tumor-associated glycoprotein-72 and carcinoembryonic antigen on malignant ascites cells', Journal of Clinical Oncology, 10, pp. 735 - 746

Greiner JW; Guadagni F; Borden EC; Ritts RE; Goldstein D; LoBuglio AF; Schlom J, 1992, 'EVIDENCE THAT RECOMBINANT INTERFERONS CAN ENHANCE THE SENSITIVITY OF THE DETECTION OF SERUM TAG-72 AND CEA IN PATIENTS DIAGNOSED WITH ADENOCARCINOMA', Journal of Immunotherapy, 11, pp. 126 - 126, http://dx.doi.org/10.1097/00002371-199202000-00021

Greiner JW; Guadagni F; Goldstein D; Borden EC; Ritts RE; Witt P; LoBuglio AF; Saleh MN; Schlom J, 1991, 'Evidence for the Elevation of Serum Carcinoembryonic Antigen and Tumor-associated Glycoprotein-72 Levels in Patients Administered Interferons', Cancer Research, 51, pp. 4155 - 4163

Goldstein D; Lewis C, 1991, 'Advances in drug delivery and targeting', Current Opinion in Oncology, 3, pp. 1096 - 1104, http://dx.doi.org/10.1097/00001622-199112000-00019

Goldstein D; O'Leary M; Mitchen J; Borden EC; Wilding G, 1991, 'Effects of interferon βser and transforming growth factor β on prostatic cell lines', Journal of Urology, 146, pp. 1173 - 1177, http://dx.doi.org/10.1016/S0022-5347(17)38034-5

Sosman JA; Hank JA; Moore KH; Borchert A; Schell K; Kohler PC; Goldstein D; Bechhofer R; Storer B; Albertini MR; Leung PE; Levitt D; Sondel PM, 1991, 'Prolonged interleukin-2 (IL-2) treatment can augment immune activation without enhancing antitumor activity in renal cell carcinom', Cancer Investigation, 9, pp. 35 - 48, http://dx.doi.org/10.3109/07357909109032798

Robinson SP; Goldstein D; Witt PL; Borden EC; Jordan VC, 1990, 'Inhibition of hormone-dependent and independent breast cancer cell growth in vivo and in vitro with the antiestrogen toremifene and recombinant human interferon-α2', Breast Cancer Research and Treatment, 15, pp. 95 - 101, http://dx.doi.org/10.1007/BF01810781

Goldstein D; Cheuvart B; Trump DL; Shiraki M; Comis RL; Tormey DC; Harris JE; Borden EC, 1990, 'Phase II trial of carboplatin in soft-tissue sarcoma', American Journal of Clinical Oncology: Cancer Clinical Trials, 13, pp. 420 - 423, http://dx.doi.org/10.1097/00000421-199010000-00011

Laszlo J; Goldstein D; Gockerman J; Hood L; Huang AT; Triozzi P; Sedwick WD; Koren H; Ellinwood EH; Tso CY, 1990, 'Phase I studies of recombinant interferon-gamma.', J Biol Response Mod, 9, pp. 185 - 193, https://www.ncbi.nlm.nih.gov/pubmed/2160521

GOLDSTEIN D; SOSMAN JA; HANK JA; WEILHILLMAN G; MOORE KH; BORCHERT A; BECHHOFER R; STORER B; KOHLER PC; LEVITT D; SONDEL PM, 1989, 'REPETITIVE WEEKLY CYCLES OF INTERLEUKIN-2 - EFFECT OF OUTPATIENT TREATMENT WITH A LOWER DOSE OF INTERLEUKIN-2 ON NON-MAJOR HISTOCOMPATIBILITY COMPLEX-RESTRICTED KILLER ACTIVITY', CANCER RESEARCH, 49, pp. 6832 - 6839, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:A1989CA66300061&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Goldstein D; Sielaff KM; Stores BE; Brown RR; Datta SP; Witt PL; Teitelbaum AP; Smalley RV; Borden EC, 1989, 'Human biologic response modification by interferon in the absence of measurable serum concentrations: A comparative trial of subcutaneous and intravenous interferon-β serine', Journal of the National Cancer Institute, 81, pp. 1061 - 1068, http://dx.doi.org/10.1093/jnci/81.14.1061

Guadagni F; Schlom J; Johnston WW; Szpak CA; Goldstein D; Smalley R; Simpson JF; Borden EC; Pestka S; Greiner JW, 1989, 'Selective interferon-induced enhancement of tumor-associated antigens on a spectrum of freshly isolated human adenocarcinoma cells', Journal of the National Cancer Institute, 81, pp. 502 - 512, http://dx.doi.org/10.1093/jnci/81.7.502

Goldstein D; Bushmeyer SM; Witt PL; Jordan VC; Borden EC, 1989, 'Effects of Type I and II Interferons on Cultured Human Breast Cells: Interaction with Estrogen Receptors and with Tamoxifen', Cancer Research, 49, pp. 2698 - 2702

Goldstein D; Levi JA; Woods RL; Russell J; Morgan J; Kerestes Z, 1989, 'Double-blind randomized cross-over trial of dexamethasone and prochlorperazine as anti-emetics for cancer chemotherapy', Oncology (Switzerland), 46, pp. 105 - 108, http://dx.doi.org/10.1159/000226695

Laszlo J; Goldstein D, 1988, 'The doctor's dilemma (the nurse's Waterloo)', Cancer Investigation, 6, pp. 361 - 363, http://dx.doi.org/10.3109/07357908809080660

Goldstein D; Laszlo J, 1988, 'The role of interferon in cancer therapy: A current perspective', CA: A Cancer Journal for Clinicians, 38, pp. 258 - 277, http://dx.doi.org/10.3322/canjclin.38.5.258

Triozzi PL; Goldstein D; Laszlo J, 1988, 'Contributions of benzodiazepines to cancer therapy.', Cancer Invest, 6, pp. 103 - 111, http://dx.doi.org/10.3109/07357908809077033

Goldstein D; Kelly R; Ralston M; Penny R; Hayes J, 1987, 'Chemotherapy influencing the course of nephrotic syndrome in colonic carcinoma', Medical Oncology and Tumor Pharmacotherapy, 4, pp. 101 - 105, http://dx.doi.org/10.1007/BF02934947

Goldstein D; Gockerman J; Tso CY; Hood LE, 1987, 'Effects of 7-Interferon on the Endocrine System: Results from a Phase I Study', Cancer Research, 47, pp. 6397 - 6401

Goldstein D; Laszlo J, 1986, 'Interferon Therapy in Cancer: From Imaginon to Interferon', Cancer Research, 46, pp. 4315 - 4329

Geczy CL; Ryan J; Walsh J; Goldstein D, 1986, 'Lymphokine‐induced monocyte procoagulant activity is depressed in patients with advanced malignancies', International Journal of Cancer, 37, pp. 677 - 682, http://dx.doi.org/10.1002/ijc.2910370506

Laszlo J; Goldstein D; Vugrin D; Hood L; Tso CY, 1986, 'Does maintenance therapy with alpha interferon stabilize cancer growth? A pilot study.', J Biol Response Mod, 5, pp. 294 - 299, https://www.ncbi.nlm.nih.gov/pubmed/3734845

Back to profile page